zeloxim solutie injectabila 15 mg
bilim pharmaceuticals a.?. - meloxicamum - solutie injectabila - 15 mg
topamax 100 mg
janssen-cilag s.p.a. - italia - topiramatum - compr. film. - 100mg - antiepileptice alte antiepileptice
topamax 50 mg
janssen-cilag s.p.a. - italia - topiramatum - compr. film. - 50mg - antiepileptice alte antiepileptice
topamax 25 mg
janssen-cilag s.p.a. - italia - topiramatum - compr. film. - 25mg - antiepileptice alte antiepileptice
zaldiar 37,5 mg/325 mg
stada arzneimittel ag - germania - combinatii (tramadolum+paracetamolum) - compr. film. - 37,5mg/325mg - alcaloizi naturali din opiu opioide in combinatie cu analgezice non-opioide
masca de protectie cu 3 pliuri de unica folosinta, model glorious
sc glorious lighting srl -
masca de protectie cu 3 pliuri de unica folosinta, model glorious i
sc glorious lighting srl -
masca de protectie cu 3 pliuri de unica folosinta, model gl i
sc glorious lighting srl -
ultibro breezhaler capsule cu pulbere de inhalat 110 mcg + 50 mcg
novartis pharma ag - indacaterolum + glicopironiu - capsule cu pulbere de inhalat - 110 mcg + 50 mcg
lonsurf
les laboratoires servier - trifluridine, tipiracil clorhidrat de - neoplasme colorectale - agenți antineoplazici - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.